` TERN (Terns Pharmaceuticals Inc) vs S&P 500 Comparison - Alpha Spread

TERN
vs
S&P 500

Over the past 12 months, TERN has underperformed S&P 500, delivering a return of -37% compared to the S&P 500's +13% growth.

Stocks Performance
TERN vs S&P 500

Loading
TERN
S&P 500
Add Stock

Performance Gap
TERN vs S&P 500

Performance Gap Between TERN and GSPC
HIDDEN
Show

Performance By Year
TERN vs S&P 500

Loading
TERN
S&P 500
Add Stock

Competitors Performance
Terns Pharmaceuticals Inc vs Peers

S&P 500
TERN
LLY
JNJ
NOVO B
ROG
Add Stock

Terns Pharmaceuticals Inc
Glance View

Market Cap
492.4m USD
Industry
Pharmaceuticals

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The company is headquartered in Foster City, California and currently employs 41 full-time employees. The company went IPO on 2021-02-05. The firm is focused on developing a portfolio of small-molecule single-agent and combination therapy candidates to address diseases, such as non-alcoholic steatohepatitis (NASH) and obesity. Its lead program, TERN-101, is a liver-distributed, non-bile acid Farnesoid X Receptor (FXR), agonist that has demonstrated a differentiated tolerability profile and improved target engagement due to its sustained FXR activation in the liver but only transient FXR activation in the intestine. Its TERN-501 is a thyroid hormone receptor beta (THR-B) agonist with metabolic stability and improved liver distribution. Its TERN-201 is an inhibitor of vascular adhesion protein-1 (VAP-1) that has demonstrated target engagement in clinical trials. Its TERN-601 is its small-molecule Glucagon-Like Peptide-1 Receptor (GLP-1R) agonist program that is intended to be orally administered for NASH and obesity.

TERN Intrinsic Value
HIDDEN
Show
Back to Top